Best regulatory submission software

Overview

Regulatory submission software helps pharmaceutical, biotech, and medical device companies assemble, validate, publish, and electronically transmit dossiers to health authorities such as the FDA, EMA, MHRA, and Health Canada. The category spans tools that handle eCTD authoring and publishing, submission tracking, document version control, audit trails, and multi-market registration management — all functions that intersect with strict GxP compliance and 21 CFR Part 11 or EU Annex 11 requirements.

This guide is written for mid-size pharma and biotech regulatory affairs teams managing an active pipeline of three to ten products across multiple markets. If your team is responsible for INDs, NDAs, BLAs, or MAAs — and you need to move submissions through FDA ESG or EMA eSubmission Gateway without rebuilding documents from scratch at every stage — this is the comparison you need.

The market is fragmented: it includes purpose-built eCTD publishing suites, all-in-one RIM platforms, eQMS tools with submission modules, consulting-backed services, and regulatory authority portals that applicants must use regardless of which software they select. Sorting those categories matters before shortlisting, because tools that look adjacent — clinical trial management systems, standalone QMS platforms, or regulatory authority portals — solve genuinely different problems.

For teams that need an integrated authoring-to-publishing pipeline with AI-native content validation and regulatory intelligence built in, Assyro is the strongest fit for the primary buyer scenario described throughout this guide. Teams with different constraints — transparent bundle pricing, medical device pathways, or multi-format regional submissions — will find specific competitors better suited to those cases in the detailed reviews below.

---

Featured Option

Assyro — AI-native regulatory submission workspace for pharma and biotech

Website: assyro.com

Best for: Pharma, biotech, and medical device regulatory affairs teams that need integrated eCTD authoring, content-level validation, and publishing in a single platform — without enterprise-scale overhead or third-party handoffs.

Assyro is purpose-built for the submission workflow: a team authors a document in Assyro's structured environment, that document feeds directly into the publishing engine, and the resulting eCTD sequence is validated against FDA CDER/CBER, EMA, Health Canada, and PMDA criteria before it leaves the platform. There is no Word-to-PDF conversion step, no bookmark-rebuilding, and no separate final-check validator.

The key differentiator is content-level validation. Where most eCTD tools check XML structure, file naming conventions, PDF technical properties, and MD5 checksums, Assyro's decision-tree logic also checks whether Module 2 QOS claims are consistent with Module 3 CMC data, whether cross-references resolve correctly, and whether evidence-to-claim gaps exist anywhere in the dossier. Those are the gaps that survive technical validators and create inspection findings or FDA Complete Response Letters.

Standout capabilities:

• AI-native decision-tree content validation: catches Module 2/3 inconsistencies, cross-reference mismatches, evidence-to-claim gaps, missing components, and outdated summaries — not only XML structure and PDF formatting
• Native authoring-to-publishing pipeline: structured documents consumed directly by the publishing engine with no Word-to-PDF conversion or bookmark rebuilding
• 340+ pre-formatted authoring templates mapped to CTD and eCTD structures
• Shared language libraries for approved safety narratives, mechanism-of-action text, and standard statements propagated across programs and indications
• Live citation links that update automatically when source data changes, with one-click traceability to source
• Regulatory intelligence covering ICH Q1–Q14, FDA, EMA, and Health Canada with automated change monitoring linked to active impact-assessment workflows — not passive email alerts
• eCTD sequence assembly with ICH eCTD conformance checking, regional validation criteria (FDA, EMA, Health Canada, PMDA), MD5 checksums, file naming enforcement, PDF technical property validation, and hyperlink integrity checking
• Role-based section ownership, review routing, approval gates, and tracked changes coordinating 15+ writers across 5 modules

Compliance frameworks: 21 CFR Part 11, 21 CFR Parts 210/211, 21 CFR Part 600, ICH CTD/eCTD, ICH Q1–Q14, ICH Q5–Q12 (biologics), ICH Q7–Q12 (CMC/CDMO), GxP, EU Annex 11

Integrations: SharePoint, Box, Google Drive

Productivity metrics (vendor-quoted): 14× faster document drafting, 50% reduction in validation time, 100+ hours recovered per NDA cycle, and $150–250K in avoided rework, contractor fees, and delays per typical NDA.

Pricing: Contact for pricing — all plans are custom-quoted. Assyro's own blog notes that most vendors in this category do not publish standardized pricing, and advises buyers to request written quotes with scope assumptions. No public tiers or dollar figures are available on any Assyro page.

Limitations to weigh:

• Regulatory intelligence currently covers FDA, EMA, and Health Canada; not a standalone database for ex-US markets beyond those three authorities
• Founded in 2025 (Antler accelerator-backed); teams evaluating long-term vendor stability, GAMP 5 documentation, or CSA validation package maturity should verify directly with Assyro
• No public pricing page — requires a sales conversation to get cost details

Review signals: No public reviews yet on G2, Capterra, or industry pharma outlets. Assyro is accepting early access applications as of 2026 and has not accumulated a public review record.

---

Shortlist of the Best Regulatory Submission Software

For teams ready to begin shortlisting, here are the strongest options across the key use cases this guide covers:

1. Assyro — Best integrated authoring-to-publishing pipeline with AI-native content validation (pharma/biotech)

2. Kivo — Best all-in-one RIM + QMS + eTMF bundle with the most transparent partial pricing in the category

3. EXTEDOpulse Submission Publishing — Best for broadest submission format coverage across eCTD v3/v4, NeeS, ACTD, IMPD, and EAEU formats

4. Veeva QuickVault — Best pre-validated Day-1-ready platform for MedTech and medical device submission workflows

5. Infiuss (Probe) — Best for decentralized clinical trial management and EDC (not an eCTD submission tool)

6. EMA eSubmission Gateway / Web Client — Mandatory free transmission channel for EMA centralised procedure submissions (not a publishing platform)

7. Instem — Life sciences regulatory submission software with limited publicly available product documentation

8. JJCC Group — Best managed consulting service for CTD dossier assembly and regulatory advisory (not a licensable SaaS product)

9. eLeaP QMS (quality.eleapsoftware.com) — Best QMS + LMS integration for inspection readiness (not an eCTD publishing tool)

10. FDA eCTD — The governing submission format specification from the regulatory authority (not a software product)

> Buyer note: Several entries in this ranked list are regulatory authority portals, consulting services, or adjacent tools. They appear because they rank in common searches for "regulatory submission software" and need to be clearly distinguished from commercial software platforms. The detailed reviews below clarify which entries solve the eCTD authoring, validation, and publishing problem.

---

How We Chose

Our evaluation focused on six criteria weighted by their relevance to the primary buyer scenario: a mid-market pharma or biotech regulatory affairs team of 10–30 staff managing 3–10 products across up to six global markets, with approximately 20 submissions per year and a target pricing anchor of 15 regulatory affairs seats across 5 active product registrations.

Evidence sources used:

• Official product feature and pricing pages for each vendor
• Competitive editorial comparison pages for recall and market scope
• G2 and Capterra review signals where publicly available

We weighted products that clearly address submission dossier assembly and formatting, regulatory agency e-submission gateway integration, document lifecycle and version control, audit trail and compliance tracking, and multi-market regulatory strategy. We de-emphasized adjacent categories — quality management systems, clinical trial management, and pharmacovigilance platforms — that share keyword overlap but solve a different core problem. When public pricing, named integrations, or user review data were not available, we said so explicitly rather than filling gaps with unsupported claims.

---

Comparison Table

The pricing scenario below uses 15 regulatory affairs seats and 5 active product registrations as the normalized comparison anchor.

---

Detailed Reviews

1. Kivo

Website: kivo.io/solutions/regulatory-submission-software

Best for: Life sciences teams that need an all-inclusive RIM, QMS, eTMF, and DMS bundle with transparent partial pricing and fast implementation — and who are comfortable routing final eCTD publishing through an external vendor.

Kivo's strongest argument in this category is simplicity of procurement: one subscription covers RIM, eTMF, QMS, and DMS with no per-module upsell, no per-study or per-GB charges, and DocuSign eSignatures included. The platform supports submission assembly for IND, NDA, BLA, MAA, 510(k), and PMA across FDA, EMA, MHRA, and global authorities, and implementation can be completed in under two weeks.

What stands out:

• Submission Builder with pre-formatted templates and placeholder structures for IND, NDA, BLA, MAA, 510(k), and PMA — live-linked to the DMS so version updates propagate automatically and export trackers are generated on demand
• eCTD Viewer for importing, viewing, archiving, and re-importing eCTD dossiers with full traceability, including a documented handoff workflow to Docubridge for final eCTD publishing
• Multi-region submission planning with country-specific requirements management, health authority commitment tracking, and real-time Kanban and Gantt views across markets in a single dashboard
• Correspondence Tracking that centralizes health authority interactions inside the DMS
• Compliance certifications included: 21 CFR Part 11, 21 CFR Part 820, Annex 11, GxP/GCP, ISO 13485, ISO 9001, ICH Q10, EU MDR, MDSAP, ALCOA+; SOC 2 and ISO 9001 certified at the platform level
• Configurable QMS: CAPA, deviation, audit, change control, risk assessment, training management with eSignature capture

Integrations: DocuSign (license included), Microsoft Office / Office 365 (online and desktop), Microsoft Azure Active Directory (SSO), Okta (SSO), Google Workspace (SSO), Slack, SharePoint (file import), Box (file import)

Pricing: Kivo publishes partial pricing. Starter / small teams: all-inclusive annual subscription starting under $10,000/year. RIM team plans: starting under $1,000/month. Enterprise reference point: approximately $85,000/year for 100 users, plus a one-time implementation and migration fee starting at $25,000 for larger teams. For 15 seats, a linear interpolation puts the likely range at $12,000–$20,000/year — but this is an estimate. No per-seat rate is published for that range; contact sales for an exact quote. No charges for maintenance, support, validation, per study, per GB, setup, or training.

User feedback: Kivo holds a 5.0/5 rating on G2 across 17 reviews. G2 reviewers consistently praise the all-in-one module coverage — one reviewer managing 15+ drug development programs reports using it daily without switching tools. The Submission Builder is called a "must-have for first IND prep" at small companies. Support is rated as highly responsive via live chat. Recurring complaints include a confusing left-side navigation panel, incomplete Microsoft @ mention integration (requires workarounds), a non-intuitive e-signature workflow, and the absence of per-SOP or per-individual training completion dashboards.

Key tradeoff: Kivo intentionally excludes a native eCTD publishing engine and relies on Docubridge for final dossier output. Teams that need a fully integrated authoring-to-publishing pipeline without a third-party handoff should evaluate Assyro, which eliminates that step. No direct FDA ESG or EMA eSubmission Gateway integration is named on Kivo's pages — electronic transmission may require separate management.

Bottom line: The most transparent pricing in the category for a full-featured RIM/QMS/eTMF bundle. Strong for teams that want proven all-in-one coverage with predictable costs and fast rollout, and are comfortable with a publishing handoff to Docubridge.

---

2. EXTEDOpulse Submission Publishing

Website: extedo.com/software/submission-management-hub/submission-publishing

Best for: Organizations managing complex multi-region portfolios with non-CTD formats — NeeS, ACTD, IMPD, VNeeS, EAEU — alongside standard eCTD v3/v4 submissions, without requiring XML expertise.

EXTEDOpulse Submission Publishing is the eCTD-focused module of EXTEDO's broader RIM platform. Its standout position in the market is format breadth: it handles eCTD v3, eCTD v4, NeeS, ACTD, eCopy, IMPD, PIP, VNeeS, DMF, ASMF, Clinical Trial Applications, and EAEU submissions in a single application. The built-in technical validation engine uses the same criteria as 35+ regulatory authorities worldwide — including EMA — which means sponsors validate against the exact same checks applied at receipt.

What stands out:

• eCTD v3 and v4 dossier assembly, validation, and publishing without XML expertise (eCTDmanager)
• Validation engine shared with 35+ global regulatory authorities including EMA
• DOCmanager parent-child dossier concept: parent-level changes automatically propagate to all child country submissions, eliminating manual revalidation for multi-region lifecycle updates including MRP and DCP procedures
• RLPmanager report-level publishing: drag-and-drop clinical study compilation, PDF merging, automated eCTD-ready hyperlinks, bookmarks, and metadata
• Structured Product Labelling (SPL) capabilities for FDA electronic submissions
• Parallel submission support: MAA, NDA, BLA, NDS, IND
• Powerful hyperlinking and bookmarking engine with detection, notification, and correction of broken links
• EXTEDOcloud delivers pre-completed IQ/OQ/PQ validation with scripts and documentation; certified under 21 CFR Part 11 and EU GMP Annex 11 Volume 4

Integrations: Generis CARA Platform, Uxopian ARender, AB Cube SafetyEasy, Alfresco Content Services, Veeva Vault (via DMSconnect), Documentum (via DMSconnect), EMA SPOR Database, EMA PMS/Pharmacovigilance Master Data System

Compliance certifications: FDA 21 CFR Part 11, EU GMP Annex 11 Volume 4, IDMP (ISO standards), E2B(R3), HL7 eMDR, XEVMPD

Pricing: Fully quote-based. EXTEDO's Plans document references three tiers — Small (≤10 users per hub), Business (≤50 users per hub), and Enterprise — but publishes no dollar figures for any tier. A 15-seat team would likely fall into the Business tier. Add-on modules — DOCmanager, RLPmanager, DMSconnect, AIxpt, MPDmanager, eDOCSmanager, SAFETYEasy — are licensed separately on top of the base Submission Management Hub, making total cost of ownership for a full RIM deployment substantially higher than the base tool alone. Contact EXTEDO sales directly for a quote.

User feedback: No publicly indexed reviews on G2, Capterra, PharmiWeb, RAPS, or Fierce Pharma as of publication.

Key tradeoff: EXTEDO's modular architecture means full end-to-end coverage requires multiple separate license add-ons. Teams that want a unified authoring-to-publishing pipeline without module-by-module procurement should compare Assyro, which provides that integration by default.

Bottom line: The strongest choice for organizations that must submit across a wide range of non-CTD regional formats alongside standard eCTD, and who need a validation engine that mirrors the criteria used by the health authorities themselves.

---

3. Veeva QuickVault

Website: quickvault.veeva.com/solutions/regulatory-submission-medical-device-software

Best for: Small and mid-size MedTech and IVD companies that need a pre-validated, Day-1-ready platform covering 510(k), PMA, De Novo, CE Mark, EU MDR/IVDR, and IMDRF submissions — without a lengthy implementation or custom validation project.

QuickVault by Veeva unifies design control, regulatory submission management, and quality management in a single pre-validated cloud environment. It is explicitly designed for the medical device pathway, not pharma eCTD workflows — a distinction that is material for this category.

What stands out:

• Pre-built submission templates for eSTAR IVD, eSTAR non-IVD, EU IVDR, EU MDR, IMDRF IVD, IMDRF non-IVD, and PreSTAR — no implementation project required before preparing a first submission
• Submission builder that directly links design control documents (DV&V records, risk management data) from the Products module into the submission package, eliminating manual copying and version drift during parallel development
• Exports an eSTAR ready-to-upload package for FDA 510(k) submissions and an organized folder structure for Notified Body submissions
• Regulatory authority interaction tracker that centralizes all post-submission FDA and global agency communications, assigns tasks for follow-up documents, and maintains an audit-ready communication history
• Version control and full audit trails on all submission documents in a validated system
• 21 CFR Part 11 / EU Annex 11-compliant electronic signatures
• Design Control Matrix (DCM) for structured management of user needs, design inputs, outputs, verification, and validation with full traceability

Integrations: FDA eSTAR submission portal (export package for manual upload); Notified Body portals (organized folder structure export). No publicly documented named third-party integrations (ERP, LIMS, Microsoft 365, Slack, Salesforce) on the vendor's pages.

Pricing: Quote-based. QuickVault references a "flexible subscription model" with "no long-term commitments" and "no hidden setup fees." Regulatory submission functionality is included at no additional charge. No tier names or per-seat dollar figures are published. Industry analyst estimates for Veeva Vault-based platforms range from approximately $50–$200 per user per month, which at 15 seats implies a rough indicative range of $750–$3,000/month — but this is unconfirmed for QuickVault specifically. Contact QuickVault sales for a scoped quote.

User feedback: G2 has a listing shell for Veeva QuickVault but surfaces no reviewable content. One analyst commentary source (FitGap) notes that the preconfigured Vault setup reduces initial build time, but that complex global submission models may require significant additional configuration beyond the packaged offering.

Key tradeoff: QuickVault does not support eCTD publishing or pharma submission pathways (NDA, BLA, ANDA, IND, MAA). A pharma or biotech regulatory affairs team should not evaluate QuickVault as an alternative to Assyro or EXTEDOpulse — it addresses a different submission type entirely. Additionally, once regulatory content, design controls, and submission history are established in the Veeva Vault ecosystem, switching costs are high and data migration is non-trivial.

Bottom line: The strongest pre-validated option for MedTech and IVD teams that need 510(k), PMA, EU MDR/IVDR, or IMDRF submission readiness on Day 1 without a lengthy implementation. Not suitable for pharma eCTD workflows.

---

4. Infiuss Health (Probe)

Website: infiuss.com/insights/regulatory-submission-management-systems

Best for: Clinical research teams at academic institutions or early-stage biotech running remote or decentralized trials who need integrated patient recruitment, EDC, and GCP compliance in a single browser-based tool.

Infiuss Health's Probe platform is a clinical trial management and electronic data capture system. It is included here because it appears in searches for regulatory submission software, but it has no eCTD publishing, dossier assembly, submission formatting, or health authority gateway capabilities. Buyers seeking FDA NDA or EMA MAA submission tooling will find zero overlap.

What stands out for its intended use case:

• AI-powered digital patient twin with 95%+ accuracy in clinical predictions, supporting "what-if" scenario modeling, disease progression simulation, and protocol design before study kick-off
• Integrated patient recruitment via access to Infiuss Health's own patient community, allowing researchers to post opportunities, interact with patients, and access curated datasets directly in-platform
• Full EDC and data management suite including protocol development, monitoring, reporting, and data analysis in a single browser-based application
• HIPAA, GDPR, and GCP (ICH guidelines) compliance built-in, with 256-bit encryption, multi-factor authentication, and role-based access controls (Principal Investigator, Collaborator roles)

Integrations: EHR/EMR systems (generic — no named vendors), wearable devices (generic), IoT devices (generic)

Pricing: $29.99 per user per month for individual researchers. At 15 users, that totals approximately $450/month or $5,400/year. Enterprise accounts receive customized pricing (no public figures). Note: this pricing was published in a Infiuss blog article, not on a dedicated pricing page.

User feedback: No public reviews on G2, Capterra, PharmiWeb, RAPS, or Fierce Pharma. Infiuss is a seed-stage company (~1–10 employees, $625K raised).

Key tradeoff: Probe has no eCTD publishing, no health authority gateway integration (FDA ESG, EMA eSubmission Gateway), and no regulatory information management features. Product registration management, variation tracking, and multi-market dossier lifecycle management are entirely absent.

Bottom line: A well-scoped tool for decentralized clinical trial execution and patient recruitment — but not a regulatory submission platform. Evaluate it only for EDC and trial management use cases, not for NDA or MAA workflows.

---

5. EMA eSubmission Gateway and Web Client

Website: ema.europa.eu/en/human-regulatory/marketing-authorisation/electronic-common-technical-document-ectd

Best for: Understanding the mandatory electronic transmission infrastructure for EMA centralised procedure submissions — not a purchasable software product.

The EMA's eSubmission Gateway (AS2/AS3 protocols) and eSubmission Web Client are the mandatory electronic channels through which pharmaceutical applicants submit eCTD-format dossiers for marketing authorisation applications, variations, renewals, and other centralised procedure submissions. The Web Client is free to access and explicitly targeted at lower-volume applicants, including SMEs. The Gateway is required for higher-volume applicants using automated transmission.

Applicants must use one of these channels — but they cannot use either to build a compliant eCTD dossier. A separate eCTD publishing tool such as Assyro or EXTEDOpulse is required to assemble and validate the dossier before transmission.

Key capabilities of the infrastructure:

• Automated technical validation feedback on receipt, with automatic upload to EMA's internal eCTD review system — no physical CD/DVD required
• eCTD format support: Module 1 Specification v3.0.4, M2–M5 v3.2.2; covers MA, CTA, Originals, Variations, Renewals, ASMF, CEP, PSUR
• Covers Centralised Procedure, Decentralised Procedure, Mutual Recognition Procedure, and National Procedure
• IRIS regulatory procedure management system for centralised procedure lifecycle tracking
• eAF (electronic Application Forms) built on FHIR XML (HL7 FHIR R5) via the PLM Portal

Pricing: Free to register for the eSubmission Web Client and Gateway. Regulatory procedural fees under Regulation (EU) 2024/568 apply per application type (per MAA, per variation, per inspection) — not structured as per-seat or subscription pricing.

Bottom line: A mandatory infrastructure layer, not a competing software product. Every pharma team targeting EMA submissions must interface with this system, and every eCTD publishing platform in this guide — including Assyro and EXTEDOpulse — produces output designed to pass EMA's technical validation on receipt.

---

6. Instem

Website: instem.com/solutions/regulatory-submission

Best for: Life sciences organizations evaluating Instem's broader regulatory and research software portfolio.

Instem is an established life sciences software company with a regulatory submission offering, but limited public product documentation was available for independent evaluation at the time of this review. The vendor's regulatory submission page does not publish feature specifics, submission format coverage, health authority integrations, or pricing details in a format that permits detailed comparison against the other tools in this guide.

Pricing: Not publicly available — contact Instem sales directly.

User feedback: No public reviews on G2, Capterra, PharmiWeb, RAPS, or Fierce Pharma were found.

Bottom line: Request a detailed product demo and feature matrix from Instem directly before including it in a shortlist. Insufficient public evidence is available to support a confident feature-by-feature comparison at this time.

---

7. JJCC Group

Website: jjccgroup.org/regulatory-submission-support-guide

Best for: Companies that want to outsource CTD/eCTD dossier assembly and regulatory advisory to an experienced consulting firm rather than license and validate a self-service software platform.

JJCC Group is an FDA regulatory compliance consulting firm, not a software vendor. It delivers managed services covering CTD dossier preparation across all five modules, QMS development, EDMS implementation advisory, and post-market surveillance — backed by scientists, toxicologists, and regulatory specialists with 30+ combined years of experience.

What the service covers:

• Full-lifecycle CTD/eCTD dossier preparation covering all 5 modules (CMC, clinical, nonclinical, M1 regional, QOS) for FDA and global health authority submissions
• Submission types: IND, NDA, BLA, 510(k), PMA, De Novo, PMTA, and NDI Notification
• EDMS implementation guidance including version control, audit trails, and electronic signatures aligned to 21 CFR Part 11
• QMS development and optimization including CAPA tracking, change control management, and audit preparation
• Computer Software Assurance (CSA) framework guidance
• Regulatory intelligence with real-time alerts on changes from FDA, EMA, EU-TPD, Health Canada, EPA, and OECD

Pricing: Custom consulting engagement — no published tiers, per-seat rates, or per-submission fees. Contact JJCC at (800) 999-7781 or Info@jjccgroup.org.

Key tradeoff: For a 15-person regulatory affairs team managing 5 active product registrations across 6 markets with 20 annual submissions, routing every submission and variation update through an external consulting firm creates a bottleneck that a licensable SaaS platform eliminates. JJCC is a strong option for teams that have not yet built internal regulatory expertise, or for companies managing occasional high-stakes submissions without a dedicated regulatory function.

Bottom line: A credible managed-service alternative for companies that are not ready to deploy and validate a software platform. Not a substitute for a self-service eCTD publishing tool for teams with ongoing, high-volume submission workflows.

---

8. eLeaP QMS (quality.eleapsoftware.com)

Website: quality.eleapsoftware.com

Best for: Regulated industries teams (pharma, medtech, biotech, manufacturing) that need an eQMS with natively integrated LMS to maintain inspection readiness and automate training workflows — not as a primary eCTD submission tool.

eLeaP is a cloud-based eQMS that combines document control, CAPA, change control, risk management, audit management, and supplier management with a natively integrated enterprise LMS. When an SOP is approved, training automatically deploys to relevant staff; when a CAPA is raised, retraining is auto-triggered. That architecture eliminates manual handoffs that regularly surface as inspection findings.

What stands out:

• Native QMS + LMS integration: SOP approval triggers automatic training deployment; CAPA events auto-trigger retraining — no re-uploading or version mismatch
• Pre-validated out of the box with IQ/OQ support package, 21 CFR Part 11 traceability matrix, and CSA risk classification documentation
• Audit management claiming 50–70% reduction in audit preparation time through automated audit trail generation and real-time evidence collection, with automatic linkage of audit findings to CAPA records
• Broad standards coverage: 21 CFR Part 11, QMSR (21 CFR Part 820), ISO 13485:2016, ISO 9001:2015, AS9100, IATF 16949, ICH Q9/Q10, EU MDR, cGMP
• ML-based predictive defect prevention analyzing process parameters, inspection results, and supplier performance patterns

Integrations: SAP (ERP), Oracle (ERP), Microsoft Dynamics (ERP), PLM systems, MES, LIMS, CRM systems (all generic integration references — no named vendors specified beyond ERP tier), API available

Pricing: Quote-based — no published tier names or dollar figures for the QMS product. A free 30-day trial (no credit card required) is available. The LMS product (a separate SKU) starts at $5.00/user/month, scaling to $0.50/user/month at 6,000+ users — but those figures apply to the LMS only and cannot be used to estimate QMS pricing.

User feedback: No public reviews found for the eLeaP QMS product specifically. Reviews available online relate to eLeaP's legacy LMS product, which is a distinct offering.

Key tradeoff: eLeaP QMS has no native eCTD publishing, eCTD validation, or health authority gateway submission capability. A mid-market pharma team managing FDA NDAs or EMA MAAs must procure a separate eCTD publishing tool, adding cost and integration complexity. There is also no submission tracking dashboard for multi-HA dossier lifecycle management or acknowledgement receipt tracking.

Bottom line: A strong QMS + LMS combination for inspection readiness and training compliance in regulated industries. Evaluate it as a complement to an eCTD publishing platform — not as a replacement.

---

9. FDA eCTD (Format Standard)

Website: fda.gov/industry/study-data-technical-conformance-guide/ectd-technical-rejection-criteria-study-data

The FDA's eCTD Technical Rejection Criteria and associated guidance documents define the format requirements that regulatory submission software must satisfy — they are not a software product. FDA CDER and CBER require NDA, BLA, ANDA, and IND submissions in eCTD format via the FDA Electronic Submissions Gateway (ESG). Technical rejection criteria cover XML backbone conformance, file naming conventions, PDF technical properties, hyperlink integrity, and MD5 checksums.

Understanding these criteria is essential for evaluating any eCTD publishing tool. Software like Assyro and EXTEDOpulse build their validation engines against these exact published criteria. Buyers should request from any vendor a full list of which FDA eCTD Technical Rejection Criteria their tool validates against and whether those checks run automatically on assembly or only at final export.

Bottom line: Not a purchasable product. Referenced here to help buyers understand what the submission format standards require, so they can ask the right technical questions of software vendors.

---

10. Gitnux (Comparison Resource)

Website: gitnux.org/best/regulatory-submission-software

Gitnux is an independent software review and comparison site that publishes ranked lists of regulatory submission tools across three interrelated pages: regulatory submission software, regulatory submissions software, and regulatory submission tracking software. Each list is scored on Features (40%), Ease of Use (30%), and Value (30%), cross-referenced against official vendor documentation and user reviews.

Gitnux is useful as a market-scanning resource. It surfaces pricing floor estimates that vendors themselves do not publish — for example, Veeva Vault Submissions at $150,000+/year, EXTEDO eCTDmanager at $50,000+/year, and GlobalSubmit VALIDATE at $10,000+/year. These are Gitnux's own estimates based on industry reports, not vendor rate cards, and should be treated as rough budget anchors rather than confirmed prices.

It is not a purchasable software product. All paths from Gitnux lead to external vendor quote requests.

---

How to Choose the Right Regulatory Submission Software

Shortlisting regulatory submission software requires more than matching feature checkboxes. The decisions below are sequential filters — work through them in order to narrow from the full market to a one- or two-vendor evaluation.

Filter 1: Clarify whether you need eCTD authoring, publishing, or both

Some teams already have documents authored in Word and simply need a publishing and validation layer. Others need a platform that covers authoring, review routing, and publishing in a connected workflow. These are different product categories.

If your team wants to eliminate the Word-to-PDF conversion step, manage cross-module consistency automatically, and have authors, reviewers, and publishers working in the same environment, Assyro is the only option in this shortlist that provides a native authoring-to-publishing pipeline with content-level validation built in. If you only need dossier assembly and publishing from pre-authored documents, EXTEDOpulse Submission Publishing covers the widest range of submission formats and validation criteria for that narrower use case.

Filter 2: Identify your submission format requirements

If your submissions are standard CTD/eCTD across FDA and EMA, most commercial platforms will cover the basics. If your portfolio includes NeeS, ACTD, VNeeS, IMPD, EAEU, or other regional non-CTD formats, that narrows the field substantially. EXTEDOpulse is the strongest option for multi-format regional portfolios. For pharma teams submitting primarily to FDA CDER/CBER, EMA, and Health Canada, Assyro validates against all three authorities natively. For MedTech and IVD teams submitting 510(k), PMA, or EU MDR/IVDR dossiers, Veeva QuickVault is purpose-built for that workflow and explicitly does not support pharma eCTD pathways.

Filter 3: Determine whether you need an all-in-one platform or a best-of-breed publishing tool

Teams managing QMS, eTMF, and regulatory submissions under one validated system with transparent pricing will find Kivo covers that need with a single subscription including RIM, eTMF, QMS, and DMS — with 17 verified G2 reviews at 5.0/5 confirming operational reliability. The tradeoff is that Kivo delegates final eCTD publishing to Docubridge, adding a handoff step. Assyro covers authoring, content validation, and publishing natively but positions as a focused submission workspace rather than a full QMS suite. Teams that need the broadest possible scope — QMS, pharmacovigilance, and submission management — should also evaluate EXTEDO's full modular suite, recognizing that each module adds separate licensing cost.

Filter 4: Assess your compliance and validation requirements

Every platform in this guide claims 21 CFR Part 11 alignment, but the depth of validation support varies significantly. Kivo includes pre-validated software updates with validation documentation and SOC 2 and ISO 9001 certification at the platform level. EXTEDOpulse delivers pre-completed IQ/OQ/PQ validation scripts via EXTEDOcloud, certified under 21 CFR Part 11 and EU GMP Annex 11 Volume 4. Assyro aligns to 21 CFR Part 11, EU Annex 11, and GxP documentation workflows with audit trails, role-based approvals, and approval gates — buyers evaluating GAMP 5 or CSA validation package depth should verify directly with Assyro given its 2025 founding date. eLeaP QMS ships with an IQ/OQ support package and Part 11 traceability matrix, making it a strong choice for inspection-readiness workflows even though it does not cover eCTD submission.

Filter 5: Compare pricing models against your budget and seat count

For the buyer scenario of 15 regulatory affairs seats and 5 active product registrations:

• Assyro: Contact for pricing — custom-quoted; invite the team to scope a quote
• Kivo: Estimated $12,000–$20,000/year based on published data points (under $10,000/year for small teams, ~$85,000/year for 100 Enterprise users); the most concrete public pricing signals in the category
• EXTEDOpulse: Contact sales — Business tier (≤50 users) applies, but no dollar figures published; add-on modules price separately
• Veeva QuickVault: Contact sales — industry estimates of $50–$200/user/month imply $750–$3,000/month unconfirmed for 15 seats
• Infiuss Probe: ~$450/month (15 × $29.99/user/month, published) — but does not address eCTD submission workflows

For teams that need to get a budget approved before entering a sales process, Kivo is the only true-software vendor in this list that provides enough public data to construct a credible budget range. For all others, including Assyro, plan for a scoped discovery call to get a written quote with assumptions.

---

Key Features to Look For in Regulatory Submission Software

The six criteria below translate directly into product requirements. Use them as an evaluation checklist during demos and RFP responses.

1. eCTD publishing and submission dossier assembly (28% of decision weight)

The platform must assemble a complete, valid eCTD sequence — XML backbone, table of contents, correct lifecycle operations (new, append, replace, delete), PDF properties, file naming, and hyperlinks — without requiring XML expertise from the regulatory affairs team. Ask vendors whether their validation runs upstream during assembly or only at the final export step. Assyro integrates validation into the authoring workflow, catching issues before they reach the publishing stage. EXTEDOpulse uses the same validation engine as 35+ regulatory authorities. Both are meaningfully different from tools that only assemble documents after they have been converted from Word.

2. Health authority gateway integration and submission tracking (22%)

A full workflow ends at the health authority's receipt confirmation, not at dossier export. Evaluate whether the platform has named integrations with FDA ESG and EMA eSubmission Gateway, or whether electronic transmission and acknowledgement tracking require a separate step. Assyro provides a submission tracking dashboard across FDA, EMA, and Health Canada. The EMA eSubmission Web Client (free) and Gateway (AS2/AS3) are mandatory transmission channels that every submission must pass through — your eCTD publishing tool must produce output that clears EMA's automated technical validation on receipt.

3. Document lifecycle and version control (18%)

Every change to a submission document must be traceable. Evaluate: Does the system enforce version numbering automatically? Can it prevent unauthorized edits to finalized content? Does it maintain a complete change history? Assyro enforces role-based section ownership with approval gates and tracked changes visible only to assigned reviewers. Kivo includes automatic version control, metadata tagging, naming convention enforcement, Document Aliases, and a secure document viewer that prevents download, print, or text copy. EXTEDOpulse provides full document versioning and version history with automated approval workflows.

4. Audit trail and 21 CFR Part 11 / GxP compliance (16%)

An inspection-ready audit trail must capture who created, modified, reviewed, approved, and transmitted every record, with timestamps and an electronic signature record that satisfies 21 CFR Part 11 and EU Annex 11. Assyro provides audit trails with traceable decisions and linked submission evidence, 21 CFR Part 11-aligned electronic records, and EU Annex 11-aligned workflows. Kivo includes granular audit trails, role-based permissions with session timeout, and SOC 2 certification. eLeaP QMS produces complete change-history audit trails and ships with a 21 CFR Part 11 traceability matrix, making it a strong complement for teams that need integrated QMS audit readiness alongside their eCTD publishing workflow.

5. Multi-market and global registration support (10%)

Managing six or more markets means maintaining separate Module 1 regional sections, tracking submission status by health authority, and propagating CMC or clinical data changes across multiple dossiers without duplicating work. Assyro covers FDA, EMA, Health Canada, and PMDA validation criteria in a single publishing workflow. EXTEDOpulse DOCmanager propagates parent dossier changes to all child country submissions automatically. Kivo provides multi-region submission planning with country-specific requirements management, health authority commitment tracking, and Kanban/Gantt views across markets. For teams with substantial ex-US portfolios including EAEU or ACTD markets, EXTEDOpulse's format breadth is the clearest advantage.

6. Validation support and system qualification documentation (6%)

GxP-regulated systems must be qualified. Ask for: IQ/OQ/PQ scripts and documentation, GAMP 5 category classification, CSA risk classification documentation, and whether pre-validated cloud deployment or executed validation scripts are included in the base subscription or priced separately. EXTEDOpulse delivers pre-completed IQ/OQ/PQ via EXTEDOcloud. Kivo includes pre-validated software updates and validation documentation with all tiers. eLeaP QMS ships with an IQ/OQ support package and Part 11 traceability matrix. Assyro aligns to GxP, 21 CFR Part 11, and EU Annex 11 — for GAMP 5 / CSA validation package specifics, request documentation directly from Assyro.

---

Pricing and Cost Considerations

Pricing in the regulatory submission software category is almost uniformly opaque. Most vendors do not publish list prices, and even vendors that publish partial pricing — like Kivo — give data points rather than per-seat rate cards. Assyro's own blog explicitly notes this dynamic and advises buyers to request written quotes with scope assumptions for every vendor on their shortlist.

Normalized cost comparison: 15 regulatory affairs seats / 5 active product registrations

Key cost drivers to clarify before signing

Module add-ons: EXTEDO prices each hub module (DOCmanager, MPDmanager, eDOCSmanager, SAFETYEasy) separately. A base Submission Publishing license does not include registration management or document management. Always ask for a full-scope quote that covers every module you expect to use.

Implementation and migration fees: Kivo references a one-time implementation and migration fee starting at $25,000 for larger teams. It is unclear whether this applies at the 15-seat scale — ask directly. Assyro's blog also notes that implementation, validation, migration, and training costs are frequently excluded from headline numbers in this category across all vendors.

Validation costs: EXTEDOcloud includes pre-completed IQ/OQ/PQ validation as part of the cloud deployment. On-premise EXTEDO deployment requires the customer to execute validation scripts. For Assyro, ask specifically what GxP validation documentation is included in the subscription versus available as a professional services engagement.

Per-submission or per-market charges: Confirm with any vendor whether pricing scales by submission count, active product registration count, or health authority market count — all three dimensions exist across different vendors in this category.

For Assyro specifically: Contact for pricing to receive a scoped quote covering your seat count, product registrations, annual submission volume, and target markets. Assyro's quote-based model is consistent with the category norm.

---

(Even) More Regulatory Submission Software to Choose From

The following options appear in searches for regulatory submission software and are worth awareness, but have thinner publicly available product evidence than the vendors reviewed above.

Veeva Submissions (veeva.com/products/veeva-submissions): Veeva Vault Submissions is the enterprise RIM and submission content management platform used by large pharma organizations. Industry estimates place it at $150,000+/year at enterprise scale. Veeva dominates the large-pharma tier but is typically priced above the mid-market buyer scenario in this guide. Contact Veeva directly; no public pricing page exists.

LORENZ docuBridge (lorenz.cc/solutions/docubridge): An established eCTD publishing solution with eCTD v3.2 and v4.0 support and IDMP publishing capabilities, noted as a publishing partner by Kivo (Docubridge). No public pricing. Relevant for teams that want a standalone publishing-only tool to complement a separate RIM or authoring platform.

MasterControl (mastercontrol.com): An electronic regulatory submission and quality management system with broad regulated-industry coverage. Gitnux estimates pricing at $50,000+/year for base modules. Public product documentation for the regulatory submission module specifically is limited on the vendor's site for independent evaluation.

Rimsys (rimsys.io): A regulatory submissions management platform for medical device companies with a focus on 510(k), PMA, and international device submissions. Limited public feature documentation available; contact sales.

DSinPharmatics (dsinpharmatics.com): A regulatory affairs services firm offering submission management and preparation services. Similar to JJCC Group — a managed service rather than a self-service SaaS platform.

---

Assyro vs Other Options

Assyro vs Kivo

Kivo includes a Submission Builder with pre-formatted IND/NDA/BLA/510(k) templates and an all-inclusive RIM, eTMF, QMS, and DMS bundle — verified by 17 G2 reviews at 5.0/5 — but explicitly lacks a native eCTD publishing engine and relies on Docubridge for final dossier output, creating a handoff step Assyro's integrated authoring-to-publishing pipeline eliminates. Kivo's published pricing anchors (under $10,000/year for small teams, approximately $85,000/year for 100 Enterprise users) give buyers a concrete budget range that Assyro's fully custom-quoted model cannot match at the shortlisting stage. Choose Kivo when a team needs proven all-in-one RIM/QMS/eTMF coverage with the most transparent pricing in the category; choose Assyro when AI-native content validation and an end-to-end eCTD publishing pipeline without third-party handoffs are the deciding factors.

Assyro vs EXTEDOpulse Submission Publishing

EXTEDOpulse offers the broadest submission format coverage available — eCTD v3/v4, NeeS, ACTD, IMPD, VNeeS, EAEU, and more — validated against the same engine used by 35+ regulatory authorities worldwide, making it the stronger choice for organizations with complex multi-region portfolios that include non-CTD formats. Assyro's differentiation is AI-native content validation (catching Module 2/3 cross-module inconsistencies and evidence-to-claim gaps that format validators miss) and a fully integrated authoring-to-publishing pipeline, whereas EXTEDOpulse requires separate module licensing for equivalent end-to-end coverage. Both are quote-only with no public pricing.

Assyro vs Veeva QuickVault

Assyro and Veeva QuickVault address different submission categories: Assyro is designed for pharma eCTD pathways (NDA, BLA, IND, MAA), while QuickVault is explicitly built for MedTech device submissions (510(k), PMA, EU MDR/IVDR, IMDRF). There is no meaningful overlap — pharma regulatory affairs teams should evaluate Assyro; MedTech teams should evaluate QuickVault. Both are quote-based with no published per-seat pricing.

Assyro vs Infiuss (Probe)

Assyro and Infiuss Probe address entirely different workflows. Assyro is an eCTD authoring, validation, and publishing platform for regulatory submissions; Probe is a clinical trial management and EDC tool with no eCTD publishing, dossier assembly, or health authority gateway capabilities. Probe's published pricing ($29.99/user/month) and AI-powered digital patient twin make it the clear choice for research teams running decentralized trials who need integrated patient recruitment and GCP compliance. Choose Assyro for NDA/MAA submission workflows; choose Infiuss Probe for remote clinical trial execution and electronic data capture.

Assyro vs JJCC Group

JJCC Group delivers a managed consulting service that prepares CTD/eCTD dossiers on the client's behalf, while Assyro is a self-service software platform that gives a regulatory affairs team the tools to author, validate, and publish dossiers internally. For a 15-person regulatory team with 20 annual submissions, a consulting model creates a bottleneck that a platform eliminates. JJCC is the right choice for organizations that do not yet have the internal regulatory expertise to operate a self-service eCTD tool or for companies managing a single high-stakes submission without an ongoing regulatory function.

---

FAQ

Which software is used for eCTD submissions to FDA?

FDA requires eCTD format for NDAs, BLAs, ANDAs, and INDs submitted via the FDA Electronic Submissions Gateway. The software used to build those submissions includes platforms like Assyro (which covers authoring, validation, and publishing natively), EXTEDOpulse (which handles assembly and validation for eCTD v3/v4 and a wide range of other formats), and Lorenz docuBridge. Kivo provides submission assembly templates and an eCTD Viewer but routes final eCTD publishing to Docubridge. Veeva Vault Submissions serves large pharma organizations. The choice depends on whether your team needs an integrated authoring-to-publishing pipeline, a publishing-only layer on top of existing authored documents, or a full RIM platform.

What is regulatory submission software, and how is it different from a QMS or CTMS?

Regulatory submission software covers the specific workflow of assembling, validating, and transmitting regulatory dossiers — eCTDs, CTDs, submission sequences — to health authorities such as FDA, EMA, MHRA, and Health Canada. A quality management system (QMS) manages CAPA, deviations, audits, and document control for ongoing GMP compliance but typically does not publish eCTD sequences or transmit them through FDA ESG or EMA Gateway. A clinical trial management system (CTMS) or EDC manages clinical study execution and data collection. These categories overlap in terminology — many platforms use "regulatory" broadly — but they solve different core problems. The most common confusion in this market is between eCTD publishing tools and eQMS platforms; both are GxP-relevant but serve different stages of the product lifecycle.

What are the main types of regulatory submissions?

For pharmaceutical and biologic products: Investigational New Drug Application (IND), New Drug Application (NDA), Biologics License Application (BLA), Abbreviated New Drug Application (ANDA), and their equivalent international pathways — Marketing Authorisation Application (MAA) at EMA, New Drug Submission (NDS) at Health Canada. For medical devices: 510(k) premarket notification, Premarket Approval (PMA), De Novo, CE Mark, EU MDR/IVDR Technical File. Post-approval: variations, renewals, supplements, and Periodic Safety Update Reports (PSURs). eCTD format is required for most major pharma submissions to FDA, EMA, Health Canada, and PMDA; medical device submissions use different formats (eSTAR for FDA, organized dossier folders for Notified Bodies).

How do FDA eCTD technical rejection criteria affect which software I should choose?

FDA's eCTD Technical Rejection Criteria define the specific checks FDA performs at receipt — XML backbone conformance, file naming conventions, PDF technical properties (font embedding, encryption, security settings), MD5 checksums, hyperlink integrity, and module-level structural requirements. A technical rejection means the submission is returned without review, restarting the review clock. Evaluate every eCTD publishing tool against the specific criteria in FDA's current Technical Conformance Guide. Ask whether validation runs automatically on assembly (as it does in Assyro) or only at a final export step. Ask whether the vendor updates validation criteria when FDA publishes new Technical Rejection Criteria guidance.

How do I approach validating a regulatory submission system under 21 CFR Part 11 and GAMP 5?

Under a Computer Software Assurance (CSA) approach (FDA's 2022 guidance), validation effort should be commensurate with risk. For a GxP-relevant regulatory submission platform, that typically means: (1) defining intended use and risk classification; (2) supplier assessment including vendor audit questionnaire and quality agreement; (3) installation qualification (IQ) confirming the system is installed correctly; (4) operational qualification (OQ) testing that the system performs per specifications; and (5) performance qualification (PQ) confirming it works as expected in your environment. EXTEDOpulse delivers pre-executed IQ/OQ/PQ via EXTEDOcloud. Kivo includes pre-validated software updates. Assyro aligns to GxP and 21 CFR Part 11 workflows — request their validation documentation package and GAMP 5 classification during vendor evaluation.

Can I use a single platform for FDA, EMA, and Health Canada submissions?

Yes, most commercial eCTD publishing platforms support multi-authority submissions, but the depth of regional coverage varies. Assyro validates against FDA CDER/CBER, EMA, Health Canada, and PMDA criteria in a single workflow. EXTEDOpulse covers the broadest range of formats and authorities. Kivo supports FDA, EMA, MHRA, and global authorities through its Submission Builder, though final eCTD publishing routes through Docubridge. Each authority also has its own Module 1 regional requirements, gateway access procedures (FDA ESG vs. EMA eSubmission Gateway), and procedural fee structures — confirm with any vendor that their platform handles region-specific Module 1 content and gateway connectivity for each target authority.

---

Conclusion

The regulatory submission software category includes purpose-built eCTD platforms, all-in-one RIM suites, eQMS tools, consulting services, and regulatory authority portals. Distinguishing between them early is the most important step in the evaluation.

For the primary buyer scenario — a mid-market pharma or biotech regulatory affairs team managing INDs, NDAs, or MAAs across multiple markets — Assyro is the strongest fit. Its integrated authoring-to-publishing pipeline eliminates the Word-to-PDF conversion and bookmark-rebuilding steps that consume time between authoring and submission. Its AI-native content validation catches Module 2/3 inconsistencies, evidence-to-claim gaps, and cross-reference mismatches that structural XML validators do not find. Regulatory intelligence covering ICH Q1–Q14, FDA, EMA, and Health Canada is built into the platform with active impact-assessment workflows rather than passive email alerts. Contact Assyro for a scoped quote covering your team's seat count, product registrations, and target markets.

The strongest alternatives for specific constraints:

• Kivo — if your team needs a proven all-in-one RIM, QMS, and eTMF bundle with the most transparent partial pricing in the category and does not require a native eCTD publishing engine
• EXTEDOpulse Submission Publishing — if your portfolio includes non-CTD regional formats (NeeS, ACTD, IMPD, EAEU) alongside standard eCTD v3/v4
• Veeva QuickVault — if your team works on medical device submissions (510(k), PMA, EU MDR/IVDR) rather than pharma eCTD pathways
• JJCC Group — if your organization needs to outsource dossier preparation rather than operate a self-service platform

For all vendors in this category, request written quotes with explicit scope assumptions — seat count, product registrations, submission volume, target health authority markets, and what validation, migration, training, and professional services costs are included or excluded. That discipline will prevent the most common budgeting surprises in this procurement.